Shares of Pharmaron Beijing Co., Ltd. (HKG:3759, SHE:300759) plummeted by 5.06% on October 30, 2024, following the company's release of its third-quarter financial results. The pharmaceutical research and development services provider reported a 12.62% decline in net profit attributable to owners compared to the same period last year, missing market expectations.
According to the filing with the Hong Kong Stock Exchange, Pharmaron Beijing's net profit for the quarter ended September 30, 2024, stood at 308.4 million yuan (approximately $43.6 million), with earnings per share of 0.1744 yuan ($0.025), down 12.93% from a year earlier. While the company's revenue increased by 10.02% year-over-year to 3.21 billion yuan ($454.6 million), it failed to offset the impact of the profit decline.
The disappointing financial performance appears to have dampened investor sentiment, leading to a sell-off in the company's shares. Analysts cited concerns over Pharmaron Beijing's slowing growth and potential margin compression as potential factors contributing to the stock's decline.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。